Skip to content

PHAST: Physical Activity in Substitution Therapy

PHAST: Influence of Exercise Training on Substance Use, Substance Craving, Quality of Life, Mental Health, Sleep, and Physical Health in Patients Suffering From Opiate Dependence While Under Substitution Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02309021
Acronym
PHAST
Enrollment
28
Registered
2014-12-05
Start date
2014-11-30
Completion date
2015-11-30
Last updated
2015-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance-related Disorders

Keywords

craving

Brief summary

The aim is to examine the effect of exercise (EX) training on individuals currently receiving ST - either opiate replacement therapy (ORT) or heroin-assisted treatment (HAT) - for their opiate dependence. Main outcome variables will be: cardiovascular fitness; consumption of substances (e.g. street heroin, cocaine, cannabis, alcohol, cigarettes) other than prescribed ST or other prescribed medications; substance craving; blood pressure; lung function; resting pulse; social interaction; self-control capacity; objective and subjective sleep; cortisol levels; quality adjusted life years (QALYs); depression; mood. Covariates are current substitution dose and psychiatric diagnoses.

Detailed description

The investigators aim is to carry out a randomized controlled trial comparing exercise training group and a control group of patients receiving substitution therapy (ST). The specific goals of the study are: 1. To understand the exercise preferences, barriers to participation, motivation, experiences and attitudes regarding exercise training in patients under ST. 2. To examine whether a 12-week exercise programme affects the mental health, subjective and objective sleep, quality of life, self-control capacity, substance craving, hair cortisol levels, secondary consumption, cardiovascular fitness, blood pressure, lung function, resting pulse, and social interaction in patients receiving ST. 3. To compare the effects of the EX and control conditions on the above-mentioned outcome variables. 4. To examine to what degree the covariates of heroin substitution dose and psychiatric comorbidities affect outcome variables. 5. To explore to what extent objective variables (cardiovascular fitness, pulse, blood pressure, lung function, cortisol, objective sleep-EEG-parameters) and subjective-psychological dimensions (subjective sleep, social interaction, symptoms of depression and anxiety, self-control, substance craving) are interrelated.

Interventions

OTHERSport
OTHERNon-sport activities

Sponsors

Psychiatric Hospital of the University of Basel
CollaboratorOTHER
University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Patient at the Ambulanter Dienst Sucht or Janus clinics in Basel Town (BS); currently under substitution therapy

Exclusion criteria

Declared unfit to participate by clinic personnel due to physical disability or severe psychological disturbance or cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Craving measured by the Brief Substance Craving Scale (translated)6 monthsCraving will be measured by the Brief Substance Craving Scale (translated)
Secondary substance consumption assessed using the Time Line Follow Back method6 monthsThis will be assessed using the Time Line Follow Back method

Secondary

MeasureTime frameDescription
Subjective sleep measured using the Insomnia Severity Index (translated)6 monthsThis will be measured using the Insomnia Severity Index (translated)
Physical activity level measured using the International Physical Activity Questionnaire6 monthsThis will be measured using the International Physical Activity Questionnaire
Perceived Stress measured using the Perceived Stress Scale (translated)6 monthsWill be measured using the Perceived Stress Scale (translated)
Depression assessed using the Allgemeine Depressionskala ( Depression Scale)6 monthsDepression will be assessed using the Allgemeine Depressionskala ( Depression Scale)
Blood pressure measured using a digital sphygmomanometer6 monthsThis will be measured using a digital sphygmomanometer
Lung function measured with a Spirobank Spirometer6 monthsLung function will be measured with a Spirobank Spirometer
Hand grip strength assessed using a Hydraulic Hand Dynamometer.6 monthsThis will be assessed using a Hydraulic Hand Dynamometer.
Quality adjusted life years assessed using the Short Form (SF)36 questionnaire6 monthsThis will be assessed using the Short Form (SF)36 questionnaire
Self control measured using the Short Self Control Scale (translated)6 monthsThis will be measured using the Short Self Control Scale (translated)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026